U.S., June 6 -- ClinicalTrials.gov registry received information related to the study (NCT07007273) titled 'Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma' on May 28.

Brief Summary: This is a single arm, open-label phase II study to assess the efficacy of single agent pembrolizumab for the treatment of advanced cutaneous sarcomas. Adult patients >=18 years old who have been diagnosed with an advanced cutaneous sarcoma without regard to race, ethnicity, and/or gender. Approximately N=17 patients are planned to be enrolled. Pembrolizumab 200 mg will be administered as 30-minute IV infusion every 21 days (3 weeks).

Study Start Date: July 01

Study Type: INTERVENTIONAL

Condition: Cutaneous Sarcoma

Intervention: D...